Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Pharmaceuticals
- Disease
- Therapeutic
- Autoimmune
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 1164
License Grant
In July 1988, the Licensee began marketing products under license for the treatment of myasthenia gravis, a disease characterized by muscle weakness and atrophy.
IPSCIO Record ID: 281651
License Grant
Under the terms of the Asset Purchase Agreement, Licensee acquires all rights, title, clinical data, composition-of-matter and use patents related to GTB-004.
License Property
GTB-004 is a fixed-dose combination tablet for the treatment of the muscle weakness associated with myasthenia gravis. GTB-004 combines pyridostigmine with an antagonist helping to reduce gastrointestinal side effects associated with pyridostigmine therapy. GTB-004 is for the treatment of myasthenia gravis.
Licensor is an immuno-oncology company focused on innovative treatments based on the Companys proprietary NK cell engager (TriKEâ„¢) platform and Multi-Target Directed Bispecific Drug Conjugate platform.
Field of Use
GTB-004 for the treatment of myasthenia gravis. GTB-004 is a fixed-dose combination tablet for the treatment of the muscle weakness associated with myasthenia gravis. GTB-004 combines pyridostigmine with an antagonist helping to reduce gastrointestinal side effects associated with pyridostigmine therapy.
Myasthenia gravis is a chronic autoimmune disease of the neuromuscular junction characterized by muscle weakness. The disease occurs in all ethnic groups and both genders. Myasthenia gravis most commonly affects adult women (onset between 20 to 40 years) and older men (onset over 60), but it can occur at any age (Myasthenia Gravis Fact Sheet; National Institute of Neurological Disorders and Stroke, 2016).
IPSCIO Record ID: 26578
License Grant
This Agreement is by and between Licensor, Trustee of the ALS Charitable Remainder Trust, dated August 28, 2006 and Licensee Charitable Trust shall transfer shares of Tribune Co. Common Stock and Berkshire Hathaway Inc. Class A and Class B Common Stock having a combined value of twenty four million five hundred thousand dollars ($24,500,000) (the royalty Shares) to an account designated by Licensee. For purposes of this Agreement, the royalty Shares shall be valued at the closing trading price of the shares on the date hereof on the New York Stock Exchange. In consideration for the transfer of the royalty Shares, Licensee shall pay to Licensor royalties based on worldwide Net Sales of Arimoclomol by Licensee and Licensee Affiliates (as hereinafter defined) for treatment of Amyotrophic lateral sclerosis (ALS).
License Property
Amyotrophic lateral sclerosis, or ALS, is a disease of the nerve cells in the brain and spinal cord that control voluntary muscle movement. Amyotrophic lateral sclerosis is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and difficulty breathing (dyspnea). ALS is the most common of the five motor neuron diseases.
IPSCIO Record ID: 295927
License Grant
Licensor granted Licensee worldwide exclusive licenses, with the right to grant sublicenses, to our patent rights and know-how with respect to such compounds and products. Licensee is responsible for pursuing worldwide clinical development of compounds from the research program and has the exclusive right to develop and commercialize compounds from the collaboration to further develop and commercialize compounds identified under our Foundation sponsored research program with the Foundation and to research other small molecule compounds with potential for therapeutic use in patients with Foundation.
License Property
Licensor developed several high-throughput drug discovery technology platforms that enable us to identify small molecule modifiers of pre-mRNA splicing. These technologies rely on sensitive quantification of pre-mRNA isoforms directly in human cells or tissue samples. Using this technology, we have successfully identified orally bioavailable small molecules that correct splicing of SMN2 mRNA. One of these molecules, risdiplam, is a potential treatment for the genetic disorder SMA.
Field of Use
The small molecule compounds with the potential for therapeutic use in patients with Spinal Muscular Atrophy (SMA).
Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy?) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body's center (distal). The muscle weakness usually worsens with age.
IPSCIO Record ID: 27459
License Grant
The Licensee licensed the exclusive North American rights to Firdapseâ„¢ pursuant to a License Agreement. The Licensor made an investment in the Licensee which the Licensee will use solely for the purpose of developing Firdapseâ„¢. The Licensee took over a Phase 3Trial previously being conducted by the Licensor and is obligated to use its diligent efforts to seek to obtain regulatory approval for and to commercialize Firdapseâ„¢ in the United States.
License Property
With the International Nonproprietary Name amifampridine, it is used as a drug, predominantly in the treatment of a number of rare muscle diseases. The phosphate salt of amifampridine, marketed as Firdapse, and is under investigation for the treatment of Lambert-Eaton myasthenic syndrome.
Firdapse® (currently approved in the EU) is the first and only approved drug for the symptomatic treatment of Lambert-Eaton Myasthenic Syndrome in adults, a rare autoimmune disease with the primary symptoms of muscle weakness.
Firdapse has been designated an orphan drug.
Field of Use
On September 29, 2014, the Licensee announced positive results from its Phase 3 Trial of Firdapse™ for the symptomatic treatment of LEMS. Both co-primary endpoints,quantitative myasthenia gravis score (QMG) and subject global impression (SGI) demonstrated statistical significance, as did a secondary endpoint for the physician’s clinical global impression of improvement (CGI-I).
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
